Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.40 |
| ▸ | FABP7 | O15540 | 2/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.39 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.39 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.39 |
| ▸ | CASP3 | P42574 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL388244 | 0.86 | KMT2A (0.58) | KMT2AEPHX2FABP5FABP7HDAC3 | |
| SCHEMBL14759878 | 0.85 | KMT2A (0.60) | KMT2AEPHX2FABP5FABP7CASP3 | |
| SCHEMBL4947412 | 0.85 | KMT2A (0.57) | KMT2AEPHX2 | |
| SCHEMBL4951870 | 0.82 | KMT2A (0.51) | KMT2AEPHX2 | |
| SCHEMBL2234362 | 0.82 | KMT2A (0.48) | KMT2AEPHX2FABP5FABP7CASP3 | |
| SCHEMBL3623157 | 0.81 | KMT2A (0.55) | KMT2AEPHX2FABP5FABP7CASP3 | |
| SCHEMBL5148061 | 0.81 | KMT2A (0.70) | KMT2AEPHX2FABP5FABP7HDAC3 | |
| SCHEMBL5972005 | 0.80 | KMT2A (0.70) | KMT2AEPHX2FABP5FABP7HDAC3 | |
| SCHEMBL2401694 | 0.80 | KMT2A (0.70) | KMT2AEPHX2FABP5FABP7HDAC3 | |
| SCHEMBL7132450 | 0.79 | KMT2A (0.54) | KMT2AEPHX2FABP5FABP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110891590-B | Glycopeptide derivative compound and use thereof | 英斯麦德公司 | 2023-07-18 | — | — | CN | disclosed |
| US-20210388028-A1 | GLYCOPEPTIDE DERIVATIVE COMPOUNDS AND USES THEREOF | BIOPHARMA CREDIT PLC (GB) | 2021-12-16 | — | — | US | disclosed |
| US-20200368312-A1 | GLYCOPEPTIDE DERIVATIVE COMPOUNDS AND USES THEREOF | INSMED INCORPORATED (US) | 2020-11-26 | — | — | US | disclosed |
| CN-110891590-A | Glycopeptide derivative compounds and uses thereof | 英斯麦德公司 | 2020-03-17 | — | — | CN | disclosed |
| US-8859506-B2 | Glycopeptide phosphonate derivatives | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC (US) | 2014-10-14 | — | — | US | disclosed |
| EP-2495251-B1 | HYDROCHLORIDE SALTS OF A GLYCOPEPTIDE PHOSPHONATE DERIVATIVE | THERAVANCE INC (US) | 2014-04-16 | — | — | EP | disclosed |
| US-20140024604-A1 | GLYCOPEPTIDE PHOSPHONATE DERIVATIVES | THERAVANCE, INC. (US) | 2014-01-23 | — | — | US | disclosed |
| US-8541375-B2 | Glycopeptide phosphonate derivatives | THERAVANCE, INC. (US) | 2013-09-24 | — | — | US | disclosed |
| WO-2013034675-A1 | PROCESS FOR THE SYNTHESIS OF TELAVANCIN AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS AS WELL AS N-PROTECTED DERIVATIVES THEREOF | SANDOZ AG (CH) | 2013-03-14 | — | — | WO | disclosed |
| WO-2013034676-A1 | PROCESS FOR THE SYNTHESIS OF TELAVANCIN, ITS PHARMACEUTICALLY ACCEPTABLE SALTS AS WELL AS AN N-PROTECTED IMINE-DERIVATIVE OF TELAVANCIN | SANDOZ AG (CH) | 2013-03-14 | — | — | WO | disclosed |
| US-20030045457-A1 | Process for preparing glycopeptide derivatives | CUMBERLAND PHARMACEUTICALS INC. | 2003-03-06 | — | — | US | disclosed |
| US-20030008812-A1 | Glycopeptide derivatives | THERAVANCE, INC. | 2003-01-09 | — | — | US | disclosed |
| US-6455669-B1 | GLYCOPROTEIN FOR USE IN THE TREATMENT AND PREVENTION OF BACTERIAL INFECTIONS | THERAVANCE, INC. | 2002-09-24 | — | — | US | disclosed |
| US-6444786-B1 | BACTERICIDES | ADVANCED MEDICINE, INC. | 2002-09-03 | — | — | US | disclosed |
| US-6392012-B1 | COMPOUND FOR USE IN TREATMENT AND PREVENTION OF BACTERIAL INFECTION | ADVANCED MEDICINE, INC. | 2002-05-21 | — | — | US | disclosed |
| US-20020022590-A1 | Useful as antibiotics; reduced tissue accumulation and/or nephrotoxicity when administered to a mammal; useful against vancomycin-resistant microorganisms | CUMBERLAND PHARMACEUTICALS INC. | 2002-02-21 | — | — | US | disclosed |
| WO-2001098328-A2 | GLYCOPEPTIDE PHOSPHONATE DERIVATIVES | THERAVANCE, INC. (US) | 2001-12-27 | — | — | WO | disclosed |
| EP-1140993-A1 | GLYCOPEPTIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | Advanced Medicine, Inc. (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2001057071-A2 | GLYCOPEPTIDE DERIVATIVES HAVING ANTIBIOTIC ACTIVITY | ADVANCED MEDICINE, INC. (US) | 2001-08-09 | — | — | WO | disclosed |
| WO-2000039156-A1 | GLYCOPEPTIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | ADVANCED MEDICINE, INC. (US) | 2000-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140024604-A1 | GLYCOPEPTIDE PHOSPHONATE DERIVATIVES | PAG1, PGLS, PTMS | KMT2A 4796/4885EPHX2 4691/4885FABP5 2120/4885 |
| US-20030045457-A1 | Process for preparing glycopeptide derivatives | GYPA, VIP, OGT | KMT2A 4121/4885EPHX2 4144/4885FABP5 3659/4885 |
| US-20030008812-A1 | Glycopeptide derivatives | MGAT3, GYPA, GIPR | KMT2A 4608/4885EPHX2 4199/4885FABP5 2718/4885 |
| US-20210388028-A1 | GLYCOPEPTIDE DERIVATIVE COMPOUNDS AND USES THEREOF | ALG1, ALG8, MUC1 | KMT2A 3866/4885EPHX2 4648/4885FABP5 3225/4885 |
| US-20020022590-A1 | Useful as antibiotics; reduced tissue accumulation and/or nephrotoxicity when administered to a mammal; useful against vancomycin-resistant microorganisms | GLS, PIGS, PAG1 | KMT2A 4773/4885EPHX2 4555/4885FABP5 1107/4885 |
| US-20200368312-A1 | GLYCOPEPTIDE DERIVATIVE COMPOUNDS AND USES THEREOF | VIP, LGALS1, NGLY1 | KMT2A 3180/4885EPHX2 4413/4885FABP5 2521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.